RECITALSResearch and Development Agreement • September 27th, 2006 • Ipg Photonics Corp • Semiconductors & related devices • New York
FORM OF AGREEMENTResearch and Development Agreement • May 5th, 2020 • England and Wales
Outdated versionResearch and Development Agreement • September 13th, 2020
Research and Development Agreement Agreement governing research and development work to be performed by a Consultant
EXHIBIT 10.8 RESEARCH AND DEVELOPMENT AGREEMENT This Research and Development Agreement ("Agreement"), effective as of March 10, 2000 ("Effective Date"), is between CytoGenix, Inc., a Nevada corporation ("CytoGenix"), and Argyll Scientific, L.L.C., a...Research and Development Agreement • September 25th, 2001 • Cytogenix Inc • Services-medical laboratories • Texas
BACKGROUNDResearch and Development Agreement • May 14th, 1998 • Allergan Specialty Therapeutics Inc • Pharmaceutical preparations • California
RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • November 27th, 2002 • Constar International Inc • Miscellaneous plastics products • Pennsylvania
This RESEARCH AND DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of November 20, 2002 between CarnaudMetalbox plc, a public limited company formed under the laws of England and Wales (“Carnaud”), Crown Cork & Seal Technologies Corporation (“Crown Technologies” and, collectively with Carnaud, the “Crown Entities”) and Constar, Inc., a Delaware corporation (“Constar, Inc.”).
EX-10.16 6 d800656dex1016.htm EX-10.16 AMENDED AND RESTATED AGREEMENT FOR RESEARCH & DEVELOPMENT ALLIANCE ON TRIEX MODULE TECHNOLOGYResearch and Development Agreement • May 5th, 2020 • New York
This AMENDED AND RESTATED AGREEMENT FOR RESEARCH & DEVELOPMENT ALLIANCE ON TRIEX MODULE TECHNOLOGY (this “Agreement”) is effective as of September 2, 2014 (the “Effective Date”) and is by and between THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (“FOUNDATION”), a non-profit educational corporation existing under the laws of the State of New York, having an office located at 257 Fuller Road, Albany, New York 12203, on behalf of the College of Nanoscale Science and Engineering (“CNSE”) of the State University of New York (the “SUNY”), and SILEVO, INC. (“SILEVO”), a Delaware corporation with its principal office located at 45655 Northport Loop East, Fremont, California 94555. FOUNDATION and SILEVO are each referred to herein sometimes individually as a “Party” or, collectively, as “Parties.”
ContractResearch and Development Agreement • January 16th, 2021 • Iowa
THIS AGREEMENT effective this _____ day of _________, 20__, by and between __________________________ (hereafter referred to as "Sponsor") and The University of Iowa, Iowa City, Iowa, a non-profit educational institution (hereinafter referred to as "University").
Agreement Between theResearch and Development Agreement • April 20th, 2012
therein contained, in all the courts of law and equity and of maritime jurisdiction, and in all the tribunals and public offices of the
EX-10.26 2 d270314dex1026.htm RESEARCH AND DEVELOPMENT AGREEMENT ***** CERTAIN INFORMATION WITHIN THIS EXHIBIT HAS BEEN OMITTED AND THE NON-PUBLIC INFORMATION HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN...Research and Development Agreement • May 5th, 2020 • Delaware
This Research and Development Agreement (the “Agreement”), effective as of November 1, 2011 (the “Effective Date”), is by and between Dexcom, Inc., a Delaware Corporation having its principal place of business at 6340 Sequence Drive, San Diego, California 92121 (“Dexcom”), and Roche Diagnostics Operations, Inc., a Delaware corporation having its principal place of business at 9115 Hague Road, Indianapolis, Indiana 46250 (“Roche”). Roche and Dexcom are each referred to herein as a “Party” and collectively as the “Parties”.
EXHIBIT 10.5 RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT WARNER-LAMBERT COMPANYResearch and Development Agreement • December 7th, 2000 • Genvec Inc • Pharmaceutical preparations • Maryland
RESEARCH AND DEVELOPMENT AGREEMENTResearch and Development Agreement • February 12th, 2007 • Opnext Inc • Semiconductors & related devices • New York
THIS RESEARCH AND DEVELOPMENT AGREEMENT is dated as of July ___, 2002, by and between HITACHI, LTD., a corporation existing under the laws of Japan (“Hitachi”) and OPNEXT, INC., a Delaware corporation and a Subsidiary of Hitachi (“OpNext”). This Agreement is deemed to be effective as of October 1, 2001 (“Effective Date”).
BETWEEN MEAT & LIVESTOCK AUSTRALIA LIMITED ABN 39 081 678 364 AND [Name Of Research Organisation] ABN [ABN] PROJECT NO. Click or tap here to enter text. Click or tap here to enter text.Research and Development Agreement • December 2nd, 2020 • New South Wales
Subject to the obligations relating to agents and subcontractors set out in clause 4 of this Agreement, the Research Organisation will engage the following agents or subcontractors to conduct a specified part (or parts) of the Project. An agent/subcontractor may conduct a part(s) of the Project for which they are listed as a “Provider” in the “Milestones, Deliverables and Payments Table” in this Schedule. The Research Organisation will notify MLA in writing of any additional agents or subcontractors that it engages after execution of this Agreement.
Agreement number: NdS/544748/2021/2021Research and Development Agreement • November 10th, 2022
Radiation therapy, together with surgical intervention and chemotherapy, is one of the most innovative and dynamically developing methods of cancer treatment. Thanks to the interdisciplinary work of physicists, biologists and doctors, clinical experience has been gained from proton treatments of over 200,000 patients in over 100 centers around the world. The development of proton therapy is a key step towards solving one of the greatest social problems of the modern world - the effective treatment of oncological patients.
DarkPulse, Inc. Signs Agreement with The University of Arizona to Develop "Intelligent Rock Bolt" for Changing Mining ConditionsResearch and Development Agreement • September 22nd, 2021
The objective of this agreement is developing monitoring techniques for reducing traumatic injuries and fatalities resulting from time-dependent physical and geologic degradation of ground openings and ground support as a result of changing mining conditions
Agreement Between a Chromogenic Modified Nijmegen- Bethesda Assay and a Qualitative ELISA test in Detection of Factor VIII Inhibitors in Plasma from Persons with Hemophilia A (PwHA)Research and Development Agreement • February 13th, 2018
• An inhibitor response via antibody development to Factor VIII (FVIII) replacement therapies is the most significant complication of hemophilia A treatment today.
Agreement No.: UMO-2020/39/B/NZ7/01913Research and Development Agreement • October 11th, 2021
• development of methodologies of encapsulation of neuroprotectants and contrast agents (fluorescent and MRI) adjusted to their physicochemical properties, for the formation of nanocarriers with the size in the range (10 - 150 nm) with surfaces functionalized for targeted delivery;
NOTE BY THE DEPARTMENT OF STATEResearch and Development Agreement • July 1st, 2015
therein contained, in all the courts of law and equity and of maritime jurisdiction, and in all the tribunals and public offices of the
Agreement for Research and Development of the “Safe Berthing/Unberthing Assist System”Research and Development Agreement • January 5th, 2023
Kawasaki Kisen Kaisha, Ltd. (“K” LINE), Kawasaki Kinkai Kisen, Ltd. (“K” LINE KINKAI), and Kawasaki Heavy Industries Co., Ltd. (KHI) have agreed to carry out the research and development of the “Safe Berthing/Unberthing Assist System” to enhance safety and efficiency of vessel maneuvering, berthing/unberthing, and mooring operations in ports.
Research and Development AgreementResearch and Development Agreement • March 7th, 2007 • Topspin Medical Inc • Electromedical & electrotherapeutic apparatus
This Research and Development Agreement (this “Agreement”), effective as of September 13, 2006 (the “Effective Date”), is entered into by and between TopSpin Medical Inc. a Delaware corporation (“TopSpin”) for itself and/or at TopSpin’s election, TopSpin Medical (Israel) Ltd., a wholly owned subsidiary of TopSpin, an Israeli corporation of 2 Yodfat St. Global Park, Lod (“TopSpin Israel”) and/or TopSpin Urology Ltd. a wholly owned subsidiary of TopSpin, an Israeli corporation of 2 Yodfat St. Global Park, Lod (“TopSpin Urology”) (TopSpin and/or TopSpin Israel and/or TopSpin Urology shall be referred to herein as the “Company”), Technion Research & Development Foundation Ltd., an Israeli corporation of the Technion City, Haifa 32000 (“TRDF”) and Dr. Aharon Blank I.D. No.029099330 of Naaman 24, Kefar Veradim (“Investigator”).
ContractResearch and Development Agreement • June 2nd, 2022
Research and Development Agreement or similar arrangement;Research and Development Agreement • March 15th, 2013
Research and Development Agreement (Pre-Commercial Procurement)Research and Development Agreement • January 20th, 2023
EX-10.3 4 dex103.htm RESEARCH AND DEVELOPMENT AGREEMENT Research and Development Agreement between: Grenzacherstrasse 124 CH-4070 Basel Switzerland (“FHLR”) and: Branford, CT 06405 USAResearch and Development Agreement • May 5th, 2020 • New York
Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the
Page 2033 TITLE 15—COMMERCE AND TRADE § 4628Research and Development Agreement • January 13th, 2022
sortium referred to in section 4622 of this title, to the extent that such participation is con- sistent with the missions of the national labora- tory.
SIXTH AMENDMENT TO AMENDED AND RESTATED AGREEMENT FOR RESEARCH & DEVELOPMENT ALLIANCE ON TRIEX MODULE TECHNOLOGYResearch and Development Agreement • October 30th, 2015 • Solarcity Corp • Construction - special trade contractors
This SIXTH AMENDMENT TO AMENDED AND RESTATED AGREEMENT FOR RESEARCH & DEVELOPMENT ALLIANCE ON TRIEX MODULE TECHNOLOGY (this “Amendment”) is effective as of September 1, 2015 (the “Effective Date”) and is by and between THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (“FOUNDATION”), a non-profit educational corporation existing under the laws of the State of New York, having an office located at 257 Fuller Road, Albany, New York 12203, on behalf of the Colleges of Nanoscale Science and Engineering of the State University of New York Polytechnic Institute), and SILEVO, LLC (“SILEVO”), a Delaware corporation with its principal office located at 45655 Northport Loop East, Fremont, California 94555. FOUNDATION and SILEVO are each referred to herein sometimes individually as a “Party” or, collectively, as “Parties.”
A SYNERGISTIC UNION OR SELLING OUT?Research and Development Agreement • May 5th, 2020
This case considers the Berkeley-Novartis agreement in light of the modern research university’s struggle to balance competition for resources against tradi- tional expectations regarding higher education’s appropriate role in society. The case also illustrates how the unique organizational features of universities impact and react to shifts in organizational mission and changes in the distribution of resources.
Research & Development AgreementResearch and Development Agreement • July 14th, 2004 • Innexus Biotechnology Inc • Pharmaceutical preparations • Washington
INNEXUS BIOTECHNOLOGY INTERNATIONAL LIMITED a company incorporated under the laws of Barbados having an office Parker House, Wildey Business Park, Wildey Road, St. Michael, Barbados and its affiliate Companies, ( “InNexus”) on one hand,
BACKGROUNDResearch and Development Agreement • October 4th, 2000 • Introgen Therapeutics Inc • Pharmaceutical preparations • Texas
EXHIBIT 10.1 CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. AMENDED AND RESTATED RESEARCH AND DEVELOPMENT AGREEMENT This Agreement, dated as of April 2, 2001, is...Research and Development Agreement • August 13th, 2001 • Arqule Inc • Pharmaceutical preparations • Massachusetts
This Research and Development Agreement (the "Agreement") is made as of the thirtieth day of June, 1999 by and between Sabratek Corporation, a Delaware corporation ("SBTK"), and Systle Corporation, a Delaware corporation ("Systle"). RECITALS A. SBTK...Research and Development Agreement • July 16th, 1999 • Sabratek Corp • Electromedical & electrotherapeutic apparatus • Illinois
AGREEMENT BETWEENResearch and Development Agreement • August 21st, 2014
HCV PROTEASE PROGRAM Research and Development Agreement between Vertex Pharmaceuticals Incorporated and Eli Lilly and Company Effective June 11, 1997Research and Development Agreement • August 14th, 1997 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Indiana
Dow Kokam, ORNL sign agreement to boost lithium ion battery performanceResearch and Development Agreement • December 14th, 2020
Research and Development AgreementResearch and Development Agreement • March 5th, 2020
